Warby Parker Inc. (NYSE: WRBY)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001504776
Market Cap 2.03 Bn
P/B 5.49
P/E 2,830.00
P/S 2.39
ROIC (Qtr) -1.35
Div Yield % 0.00
Rev 1y % (Qtr) 15.19
Total Debt (Qtr) 232.53 Mn
Debt/Equity (Qtr) 0.63

About

Warby Parker Inc., known by the ticker symbol WRBY, is a company that operates in the lifestyle, design, technology, healthcare, and social enterprise industries. As a pioneer of the direct-to-consumer model, Warby Parker has disrupted the traditional eyewear industry by providing high-quality products at affordable prices. Warby Parker's main business activities involve the design, manufacturing, and sale of prescription eyeglasses, sunglasses, and contact lenses. The company operates in the United States and Canada, with a network of retail stores...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 107.44M provides robust 0.46x coverage of total debt 232.53M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 280.36M provide 9.79x coverage of short-term debt 28.64M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 706.92M provides 3.04x coverage of total debt 232.53M, indicating robust asset backing and low credit risk.
  • Tangible assets of 706.92M provide exceptional 32.14x coverage of deferred revenue 22M, showing strong service capability backing.
  • Robust tangible asset base of 706.92M provides 3.33x coverage of working capital 211.99M, indicating strong operational backing.

Bear case

  • Operating cash flow of 107.44M barely covers its investment activities of (69.65M), with a coverage ratio of -1.54, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • The company's operating cash flow of 107.44M shows concerning coverage of stock compensation expenses of 36.89M, with a 2.91 ratio indicating potential earnings quality issues.
  • Operating earnings of (7.90M) show weak coverage of depreciation charges of 52.74M, with a -0.15 ratio indicating high capital intensity and potential reinvestment needs.
  • High depreciation of 52.74M relative to operating cash flow of 107.44M, which is 0.49x suggests significant maintenance capital requirements affecting free cash flow.
  • Cash position of 280.36M provides only -30.31x coverage of interest expenses of (9.25M), indicating potential refinancing risks in a rising rate environment.

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 209.14 Bn 76.14 21.76 0.00 Bn
2 BDX Becton Dickinson & Co 58.36 Bn 34.78 2.67 19.18 Bn
3 ALC Alcon Inc 39.57 Bn 37.80 3.89 5.24 Bn
4 RMD Resmed Inc 37.01 Bn 25.74 7.04 0.85 Bn
5 WST West Pharmaceutical Services Inc 19.95 Bn 40.58 6.61 0.30 Bn
6 HOLX Hologic Inc 16.94 Bn 29.95 4.13 2.52 Bn
7 COO Cooper Companies, Inc. 16.64 Bn 44.39 4.07 2.51 Bn
8 SOLV Solventum Corp 15.00 Bn 9.84 1.79 5.14 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 2.79 3.14
EV to Cash from Ops. EV/CFO 18.35 37.60
EV to Debt EV to Debt 8.48 23.10
EV to EBIT EV/EBIT -249.51 50.25
EV to EBITDA EV/EBITDA 43.95 19.58
EV to Free Cash Flow [EV/FCF] EV/FCF 52.15 -19.40
EV to Market Cap EV to Market Cap 0.97 -1.68
EV to Revenue EV/Rev 2.32 171.31
Price to Book Value [P/B] P/B 5.49 6.03
Price to Earnings [P/E] P/E 2,830.00 204.20
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -1.11
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.52
Dividend per Basic Share Div per Share (Qtr) 0.00 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 8.75
Interest Coverage Int. cover (Qtr) 0.85 -119.10
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -16.31 -55.01
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 11.68 200.65
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -1.49
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 90.28 -56.39
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 684.53 -106.80
EBIT Growth (1y) % EBIT 1y % (Qtr) 81.31 -36.51
EBT Growth (1y) % EBT 1y % (Qtr) 104.23 -47.44
EPS Growth (1y) % EPS 1y % (Qtr) 103.70 -15.70
FCF Growth (1y) % FCF 1y % (Qtr) 15.89 59.41
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 12.63 68.22
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 1.20 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.03
Cash Ratio Cash Ratio (Qtr) 2.12 2.49
Current Ratio Curr Ratio (Qtr) 2.61 7.77
Debt to Equity Ratio Debt/Equity (Qtr) 0.63 0.55
Interest Cover Ratio Int Coverage (Qtr) 0.85 -119.10
Times Interest Earned Times Interest Earned (Qtr) 0.85 -119.10
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 5.30 -2,368.64
EBIT Margin % EBIT Margin % (Qtr) -0.93 -2,472.65
EBT Margin % EBT Margin % (Qtr) 0.16 -2,442.59
Gross Margin % Gross Margin % (Qtr) 54.40 30.07
Net Profit Margin % Net Margin % (Qtr) 0.10 -2,438.52